BACKGROUND AND PURPOSE: The clinical significance of sentinel headaches in patients with subarachnoid hemorrhage (SAH) is still unknown. We investigated whether patients with a sentinel headache (SH) have a higher rate of rebleeding after SAH. METHODS: An SH was defined as a sudden, severe, unknown headache lasting >1 hour with or without accompanying symptoms, not leading to a diagnosis of SAH in the 4 weeks before the index SAH. Age, sex, smoking status, clinical grade, computed tomography (CT) findings, angiographic findings, placement of an external ventricular drain, and time to aneurysm obliteration were prospectively recorded. All rebleeding events were confirmed by CT. Outcome was assessed at 6 months according to the modified Rankin Scale. RESULTS: Of 237 consecutive patients with SAH, 41 (17.3%) had an SH. Rebleeding occurred in 23 (9.7%) of all patients. Patients with an SH had a 10-fold increased odds of rebleeding compared with patients without SH. Aneurysm size and the total number of aneurysms were also significantly associated with rebleeding. There were no differences in age, sex, smoking, CT or angiographic findings, external ventricular drain placement, or time to aneurysm obliteration between groups. Patients with rebeeding had a significantly worse outcome. Logistic regression revealed the presence of an SH as an independent risk factor for rebleeding. CONCLUSIONS: In our study, patients with SAH who had an SH constituted a special group of patients with a 10-fold odds for early rebleeding. The presence of an SH may select candidates for ultraearly aneurysm obliteration or drug treatment.
BACKGROUND AND PURPOSE: The clinical significance of sentinel headaches in patients with subarachnoid hemorrhage (SAH) is still unknown. We investigated whether patients with a sentinel headache (SH) have a higher rate of rebleeding after SAH. METHODS: An SH was defined as a sudden, severe, unknown headache lasting >1 hour with or without accompanying symptoms, not leading to a diagnosis of SAH in the 4 weeks before the index SAH. Age, sex, smoking status, clinical grade, computed tomography (CT) findings, angiographic findings, placement of an external ventricular drain, and time to aneurysm obliteration were prospectively recorded. All rebleeding events were confirmed by CT. Outcome was assessed at 6 months according to the modified Rankin Scale. RESULTS: Of 237 consecutive patients with SAH, 41 (17.3%) had an SH. Rebleeding occurred in 23 (9.7%) of all patients. Patients with an SH had a 10-fold increased odds of rebleeding compared with patients without SH. Aneurysm size and the total number of aneurysms were also significantly associated with rebleeding. There were no differences in age, sex, smoking, CT or angiographic findings, external ventricular drain placement, or time to aneurysm obliteration between groups. Patients with rebeeding had a significantly worse outcome. Logistic regression revealed the presence of an SH as an independent risk factor for rebleeding. CONCLUSIONS: In our study, patients with SAH who had an SH constituted a special group of patients with a 10-fold odds for early rebleeding. The presence of an SH may select candidates for ultraearly aneurysm obliteration or drug treatment.
Authors: Oliver M Mueller; Marc Schlamann; Daniela Mueller; I Erol Sandalcioglu; Michael Forsting; Ulrich Sure Journal: Ther Adv Neurol Disord Date: 2011-09 Impact factor: 6.570
Authors: S Oda; M Shimoda; A Hirayama; M Imai; F Komatsu; H Shigematsu; J Nishiyama; M Matsumae Journal: AJNR Am J Neuroradiol Date: 2015-05-14 Impact factor: 3.825
Authors: Albert J Schuette; Ferdinand K Hui; Nancy A Obuchowski; Raymond R Walkup; Charles M Cawley; Daniel L Barrow; Owen B Samuels Journal: Neurocrit Care Date: 2013-08 Impact factor: 3.210
Authors: Ramazan Jabbarli; Mukesch Shah; Christian Taschner; Klaus Kaier; Beate Hippchen; Vera Van Velthoven Journal: Neuroradiology Date: 2014-07-24 Impact factor: 2.804